Enucleated Hematopoietic Cells for Targeted Immune Tolerance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune diseases, inflammatory diseases, and allergies often involve broad immunosuppression, leading to significant morbidities and lack long-term efficacy, with risks of severe anaphylaxis and side effects.
Innovation Solution
Development of isolated enucleated hematopoietic cells expressing specific antigens, known as EHCs, which induce immune tolerance by selectively modulating the immune system, reducing antigen-specific immune cells and increasing regulatory T cells, thereby managing diseases with fewer side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If broad immunosuppression is used to treat autoimmune diseases, then immune activation is suppressed, but susceptibility to infection increases and significant morbidities occur
Solution Approach 1:
The invention segments the immune system into two distinct pathways: one targeting pathogenic immune activation (to be suppressed) and another maintaining protective immune function (to be preserved). This is achieved by using antigen-specific tolerogenic cells that selectively modulate only the antigen-specific immune response while leaving broader immune surveillance intact, thereby resolving the contradiction between suppressing immune activation and maintaining protection against infections.
Solution Approach 2:
The invention applies local quality by using tolerogenic cells that express specific antigens to create a localized immunomodulatory effect. These cells deliver suppression specifically to antigen-specific T cells through direct cell-to-cell contact or antigen presentation, while other immune cells and pathways remain unaffected. This localized approach allows suppression of pathogenic responses without the systemic immunosuppression that causes increased infection susceptibility.
2Object-affected harmful factors
If generalized immunosuppression is used, then immune activation is reduced, but long-term efficacy is lacking and severe side effects occur
Solution Approach 1:
The invention employs preliminary action by using antigen-specific tolerogenic cells that are prepared in advance and administered to induce long-lasting immune tolerance. These tolerogenic cells establish persistent regulatory mechanisms that continue to suppress pathogenic immune responses over extended periods, providing durable efficacy without the need for continuous high-dose immunosuppression that leads to side effects and loss of effectiveness.
3Object-affected harmful factors
If antigen-specific tolerogenic cells are used, then selective immune modulation is achieved, but cell complexity increases
Solution Approach 1:
The invention uses antigen-specific tolerogenic cells as intermediary agents to mediate selective immune modulation. These intermediary cells serve as a bridge between the administered antigen and the immune system, delivering targeted suppression through their antigen expression and tolerogenic properties. This intermediary approach achieves precise antigen-specific effects without requiring direct manipulation of complex immune cell populations, thereby managing complexity while maintaining selectivity.
Data Source
AI summary
Provided are cells containing exogenous antigen and uses thereof.